

10 August 2009

Financial Update – Israeli Tax Position on licensing income received

- Agreement reached on Israeli tax position on ATL/TV1102 licensing income
- US\$1.5 Mill held in Israeli trust account expected to be returned to ANP

As previously advised and as agreed with the Israeli Tax Authority (ITA), a portion of the US\$6Mill milestone payments received to date from Teva Pharmaceuticals Industries (Teva) in relation to the licensing Agreement on ATL/TV1102 is being held in a trust account in Israel pending determination on the tax liability on these payments.

An agreement has now been reached with the ITA on the tax payable on this licensing income. Accordingly, Antisense Therapeutics (ANP) expects to receive, subject to the fulfilment of certain procedures and after lodgement of the tax return and its acceptance by the ITA, in the order of US\$1.5Mill from the total funds set aside in this trust account.

Upon receipt of this return of funds held in trust, ANP will forward approximately one-third of these monies to Isis Pharmaceuticals Inc (Isis) in line with the ANP/Isis licensing agreement on ATL/TV1102.

While the timing of when Antisense Therapeutics will receive the return of funds from the trust account is yet to be confirmed, once received these funds will appear in the relevant future quarterly cash flow report for that period.

About Antisense Therapeutics Limited: Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialize antisense pharmaceuticals for large unmet markets. ANP has two drugs in development and two drugs in pre-clinical research. ATL/TV1102 (injection) has completed a Phase IIa trial as a potential treatment of multiple sclerosis. ATL1103 is a second-generation antisense drug designed to lower blood IGF-I levels and is in pre-clinical development as a potential treatment for acromegaly and vision disorders. ATL/TV1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation antisense drug at the pre-clinical research stage being investigated as a potential treatment for prostate cancer. ATL/TV1102 has been licensed to Teva Pharmaceutical Industries Ltd.

Contact Information:

Website: www.antisense.com.au
Managing Director – Mark Diamond +61 3 9827 8999
Investor Relations – Simon Watkin +61 (0) 413 153272